Lupin gets EIR from USFDA for Pithampur unit

Written by Farhat Nasim Published On 2019-04-02T12:35:47+05:30 | Updated On 2 April 2019 12:35 PM IST

Lupin gets EIR from USFDA for Pithampur unit

Lupin said its Pithampur Unit-3 facility is involved in the manufacture of metered dose inhalers (MDis), dry powder inhalers (DPis) and topical formulations for the regulated markets.

New Delhi: Drug major Lupin Ltd Tuesday announced receipt of the Establishment Inspection Report (EIR) from the US health regulator for its Pithampur facility in Madhya Pradesh.

The US Food and Drug Administration (USFDA) gives EIR on closure of inspection of an establishment that is the subject of USFDA or USFDA-contracted inspection.

"The inspection was conducted between October 8, 2018 to October 18, 2018," the company said in a BSE filing.

Also Read: Lupin, Aurobindo Pharma recalls multiple lots of BP drug including VALSARTAN

The company said its Pithampur Unit-3 facility is involved in the manufacture of metered dose inhalers (MDis), dry powder inhalers (DPis) and topical formulations for the regulated markets.

Commenting on the development, Nilesh Gupta, Managing Director, Lupin said, "Receiving the EIR for our Pithampur Unit-3 facility is a very positive development and brings us one step closer to bringing important MDis and DPis to the market. We are committed to ensuring the quality, safety and efficacy of the products that we manufacture across our facilities."

Also Read: Lupin launches generic version of Lidex Ointment

Economy of IndoreEIRIndiaLupinLupin LimitedLupin Ltdlupin MPLupin MP facilityMadhya PradeshMajorManaging directorNilesh Guptapharmapharma newspharma news indiaPithampurPithampur facilityPithampur unitUnited StatesUS Food and Drug Administration

Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Farhat Nasim

Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here